NAD+ vs. Sermorelin: Which Longevity Treatment Is Right for You?

Short answer: NAD+ and sermorelin aren't competing treatments — they support different systems (cellular energy vs. the growth-hormone axis). Neither is FDA-approved for longevity; pick based on which system you and a provider are trying to support.

NAD+ and sermorelin are two of the most popular starting points in longevity medicine, and one of the most common questions is which one to try first. The honest answer is that they're not really competing for the same job — they support two different biological systems, and for a lot of people the better question isn't "which one" but "which system am I actually trying to support."

Two Different Systems, Not Two Competing Treatments

NAD+ and sermorelin target fundamentally different biology. NAD+ is a coenzyme that supports mitochondrial energy metabolism and DNA repair at the cellular level. Sermorelin works at the hormonal level — it's a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to secrete the body's own growth hormone.^[1]

Both address a real, well-documented form of age-related decline, just from different angles. NAD+ levels fall with age due to increased activity of NAD+-consuming enzymes like CD38. Growth hormone secretion falls even more dramatically — from roughly 150 mcg/kg/day during puberty to about 25 mcg/kg/day by age 55.^[2]

What Each One Actually Requires to Work

This is a genuinely useful practical difference: because sermorelin works by stimulating your ownpituitary rather than replacing a hormone directly, it needs a functioning pituitary gland to do anything at all. Research notes that growth hormone secretagogues like sermorelin have limited effect in people whose GH deficiency stems from actual pituitary dysfunction — which isn't a concern for most people considering it for normal age-related decline, since their pituitary remains largely intact and responsive.^[3]

Regulatory Status: Neither Is FDA-Approved for This Use

Neither compound carries FDA approval for anti-aging or longevity use in adults. Sermorelin's only FDA-approved use — under the now- discontinued brand Geref — was for diagnosing and treating pediatric growth hormone deficiency. NAD+ has no FDA-approved therapeutic indication at all and is used exclusively off-label or as a compounded product.

What the Human Evidence Actually Supports for Each

Sermorelin (and related GHRH analogs) has shown, in small, short-duration randomized trials in older adults, real increases in lean body mass and IGF-1 levels — though its effect on sleep quality specifically has been mixed in placebo-controlled research.

NAD+'s human evidence looks different in kind rather than just in strength: research has established that oral precursors like nicotinamide riboside are bioavailable and reliably raise blood NAD+ levels — but no controlled human trial has yet shown that raising this biomarker actually produces a proven anti-aging or disease-prevention outcome.^[1]

One Thing Worth Discussing With Your Provider

Both compounds involve a proliferative signaling pathway, which is worth a real conversation with a licensed provider rather than something to self-assess — not because either is inherently dangerous, but because it's exactly the kind of personal-history question a provider is positioned to evaluate properly. Growth hormone and IGF-1 promote cell proliferation, which is why GH secretagogues like sermorelin are generally considered inappropriate for people with active malignancy or a history of pituitary tumors. NAD+ carries a related but mechanistically distinct theoretical consideration: certain FDA-approved cancer therapies (PARP inhibitors) work specifically by depleting NAD+ at DNA-damage sites, so there's a theoretical — not proven — interaction to be aware of if cancer treatment is part of your history.

Neither of these is a reason to avoid either compound outright — they're exactly the kind of personal and family history questions worth bringing to whoever's prescribing.

The Bottom Line

This isn't really an either/or decision based on which one "works better" — it's about which system you and your provider are trying to support. Sermorelin is the better fit if you're specifically interested in the growth-hormone/body-composition axis. NAD+ is the better fit if cellular energy and mitochondrial support is the goal. Some longevity programs offer both, since they're genuinely complementary rather than competing. Both are still early-stage in terms of human evidence relative to how confidently they're marketed — worth knowing going in, and worth discussing directly with whichever provider you choose.

If you're trying to decide between the two, NAD+ and peptide pricing across Longevity providers is a good next step — pricing, delivery format, and which compounds each one actually offers vary meaningfully across providers.

Frequently Asked Questions